secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001551152-23-000015
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie lowers 2023 adjusted EPS guidance by $0.08 on $150M Q1 IPR&D expense
---------------------------------------------------------------------------

- Q1 2023 acquired IPR&D and milestones expense of $150M pre-tax reduces GAAP and adjusted EPS by $0.08.
- Q1 2023 adjusted diluted EPS guidance lowered to $2.31-$2.41 from $2.39-$2.49.
- Full-year 2023 adjusted diluted EPS guidance lowered to $10.62-$11.02 from $10.70-$11.10.
- Company does not forecast future IPR&D and milestones expense; guidance excludes any beyond Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000015/0001551152-23-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000015/abbv-20230405.htm
  HTML page:      https://secwatch.observer/filing/0001551152-23-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer